Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition characterized by the immune-mediated destruction of insulin-producing β-cells in the pancreas, resulting in absolute insulin deficiency [1]. It affects individuals of all ages but is most commonly diagnosed during childhood and adolescence. Globally, the incidence of T1DM has been steadily rising by approximately 3–5% annually, particularly in younger age groups. As of recent estimates, more than 8.7 million people live with T1DM worldwide, and this number is expected to exceed 13 million by 2040 [2]. The disease imposes a lifelong requirement for insulin therapy, diligent glucose monitoring, and careful lifestyle adjustments to prevent acute complications such as diabetic ketoacidosis (DKA) and severe hypoglycemia, as well as long-term complications like retinopathy, nephropathy, and cardiovascular disease [3]. Effective glycemic control remains the cornerstone of T1DM management. Landmark studies, such as the Diabetes Control and Complications Trial (DCCT), have demonstrated that intensive insulin therapy aimed at maintaining near-normal blood glucose levels can significantly reduce the risk of diabetes-related complications [4]. However, achieving and sustaining tight glycemic targets remains a major challenge for many patients due to the complex nature of insulin therapy, variability in insulin sensitivity, lifestyle factors, and fear of hypoglycemia.

Traditionally, glycemic control has relied heavily on self-monitoring of blood glucose (SMBG), where patients perform capillary blood glucose testing using a glucometer. While SMBG is a valuable tool, it offers only intermittent, static data and often fails to capture critical fluctuations in glucose levels, especially during nocturnal periods, exercise, or illness. Infrequent monitoring may lead to unrecognized hypoglycemia or hyperglycemia, contributing to suboptimal glycemic control and increased risk of complications [5][6]. The advent of continuous glucose monitoring (CGM) systems has revolutionized diabetes care by providing dynamic, real-time information about glucose trends. CGM devices measure interstitial glucose levels every few minutes via a subcutaneous sensor, offering insights into time-in-range (TIR), time-above-range (TAR), and time-below-range (TBR), as well as glycemic variability [7]. Some CGM systems also include predictive alerts and alarms that help patients proactively manage impending hypo- or hyperglycemic episodes. This continuous feedback loop enhances decision-making and allows for more precise insulin dose adjustments, dietary changes, and activity planning [8]. Numerous randomized controlled trials and meta-analyses have shown that CGM use leads to significant reductions in HbA1c levels, particularly in patients with poorly controlled diabetes. In addition to improving traditional metrics, CGM has been shown to increase TIR—a parameter now recommended by the International Consensus on Time in Range as a key outcome in diabetes management [9,10]. Each 10% increase in TIR has been associated with a substantial reduction in the risk of microvascular complications.

Beyond clinical metrics, CGM also addresses important psychosocial and behavioral aspects of diabetes. Studies report that CGM use improves treatment satisfaction, reduces anxiety around hypoglycemia, enhances sleep quality, and supports better emotional well-being [11]. This is especially valuable in patients who experience frequent nocturnal hypoglycemia or hypoglycemia unawareness—two of the most distressing and dangerous complications of insulin therapy. Despite the well-established short-term benefits of CGM, there is a relative paucity of data on its long-term impact, particularly when it comes to sustained glycemic control, treatment adherence, and overall quality of life. Many existing studies are limited by short follow-up durations, small sample sizes, or selective populations (e.g., tech-savvy users or those with access to comprehensive diabetes care). Furthermore, long-term adherence to CGM, its effects on daily functioning, and cost-effectiveness over extended periods remain areas requiring deeper investigation.

Objective

To evaluate the long-term effects of continuous glucose monitoring on glycemic control (HbA1c, TIR) and quality of life in patients with Type 1 Diabetes Mellitus.

Study Design

A prospective, longitudinal cohort study involving 110 patients with T1DM was conducted at Services hospital, Lahore during January 2023 to January 2024.

Inclusion Criteria

• Diagnosed with Type 1 Diabetes for at least 1 year
• Aged 18–60 years
• Willing to participate and give informed consent
• No prior use of CGM in the past 6 months

Exclusion Criteria

• Comorbid chronic illnesses affecting glucose metabolism
• Pregnancy or planned pregnancy during the study period
• Cognitive impairment preventing proper use of CGM

Data Collection

Data for this study were collected from 110 patients diagnosed with Type 1 Diabetes Mellitus who met the inclusion criteria and provided informed consent. Participants were divided into two equal groups: one using continuous glucose monitoring (CGM) devices and the other using traditional self-monitoring of blood glucose (SMBG) methods. Baseline assessments were conducted prior to the intervention, with follow-up data collected at 6 and 12 months. Glycemic control was evaluated using HbA1c levels and time-in-range (TIR), with TIR data obtained directly from CGM reports in the intervention group and estimated from structured glucose logs in the SMBG group. Additionally, quality of life was measured using the validated Diabetes-Specific Quality of Life (DSQOL) questionnaire at each time point. All participants received standard diabetes care and education throughout the study, and data were collected under consistent conditions by trained staff to ensure accuracy and reliability.

Statistical Analysis

Statistical analysis was performed using SPSS version 26.0. Descriptive statistics, including means, standard deviations, and percentages, were used to summarize the demographic and clinical characteristics of participants in both the CGM and SMBG groups. To assess within-group changes over time, paired t-tests were used to compare baseline, 6-month, and 12-month measurements for variables such as HbA1c, time-in-range (TIR), and quality of life scores. Between-group differences were evaluated using independent t-tests for continuous variables and Chi-square tests for categorical variables. Statistical significance was determined using a p-value threshold of <0.05. Data were also checked for normality and homogeneity of variance prior to conducting inferential tests. All results were interpreted with a 95% confidence interval to ensure robustness and minimize the likelihood of type I errors

At the beginning of the study, both the CGM and SMBG groups were well matched in terms of demographics and clinical background. The average age across both groups was around 28 years, with nearly equal numbers of men and women. The duration of diabetes was just over 9 years on average in each group. Both groups had similar body mass indexes (about 24 kg/m²), and nearly all participants were using a basal-bolus insulin regimen. Importantly,   baseline  HbA1c   levels   were   also   nearly identical—8.4% in the CGM group and 8.3% in the SMBG group—confirming that both groups started on equal footing in terms of glycemic control.

Over the 12-month period, the CGM group showed a remarkable improvement in blood sugar control. Their HbA1c dropped from 8.4% to 7.3%, a full 1.1% reduction, while the SMBG group saw only a modest drop from 8.3% to 7.9%. Additionally, the CGM group increased their time in the healthy blood glucose range (70–180 mg/dL) from 52% to 74%—a 22% improvement. In comparison, the SMBG group improved from 51% to only 59%. These differences were statistically significant and show that CGM helps patients stay in better control of their glucose levels.

The CGM group experienced a clear reduction in both low and high blood sugar events. Mild hypoglycemia episodes fell by more than half—from about 4 per month to under 2. Severe hypoglycemia dropped from an average of just over 1 event per month to near zero (0.3). In contrast, the SMBG group had only a small improvement in these metrics. For high blood sugar, CGM users went from 5.5 to 2.6 events per month, while the SMBG group still had nearly 5 episodes by the end of the study. This suggests CGM is highly effective in helping patients avoid dangerous glucose extremes.

Patients using CGM reported significant improvements in their overall quality of life. Physical well-being scores rose from 16.5 to 21.2 out of 25, and emotional health improved from 15.1 to 21.0. Social functioning increased to 22.3, and treatment satisfaction reached 23.6—very close to the maximum score. On the other hand, the SMBG group showed more modest improvements in all areas. These results highlight that CGM not only improves blood sugar levels but also makes daily life with diabetes feel more manageable, less stressful, and more satisfying.

Patients using CGM checked their glucose more than twice as often as those in the SMBG group—about 10 times per day versus just under 4. They also missed fewer insulin doses—less than one per week compared to 1.5 in the SMBG group. CGM users wore their devices nearly every day, averaging 27 out of 30 days per month. These findings suggest that CGM helps patients stay more engaged with their care, possibly because the feedback is easier to access and more useful than traditional methods.

By the end of the study, 58% of CGM users had lowered their HbA1c to 7% or less, compared to only 31% of SMBG users. Two-thirds of the CGM group achieved over 70% time-in-range, while less than one-third of the SMBG group reached that goal. Hospital admissions were also lower in the CGM group (only 2%) versus 11% in the SMBG group. Furthermore, 81% of CGM users reported at least a 20% improvement in quality of life, compared to 54% in the SMBG group. Satisfaction was also higher—90% of CGM users gave high ratings to their care, while only 68% of SMBG users did. These results show that the benefits of CGM are not only clinical but also deeply personal and practical in everyday life.

This study demonstrates that long-term use of continuous glucose monitoring (CGM) significantly improves glycemic control, reduces both hypoglycemia and hyperglycemia episodes, enhances quality of life, and improves treatment adherence in patients with Type 1 Diabetes Mellitus (T1DM), compared to traditional self-monitoring of blood glucose (SMBG). At baseline, there were no statistically significant differences between the two groups in terms of demographic and clinical characteristics Table 1, ensuring a balanced comparison. Both groups had similar mean ages, gender distribution, duration of diabetes, and baseline HbA1c levels. This comparability supports the internal validity of the study outcomes. Over a 12-month period, patients using CGM experienced a significantly greater reduction in HbA1c levels (from 8.4% to 7.3%) compared to the SMBG group (from 8.3% to 7.9%), with a mean difference of 0.6% between groups (p<0.01). These results are consistent with previous research, which has consistently shown that CGM use is associated with a clinically significant improvement in long-term glycemic control [12]. Similarly, the improvement in time-in-range (TIR) was greater in the CGM group, increasing by 22% compared to a 7.9% increase in the SMBG group (p<0.01), which also aligns with trends reported in earlier studies showing that CGM helps patients spend more time within the target glucose range [13].

Table 1: Baseline Demographic and Clinical Characteristics of Participants

Episodes of hypoglycemia were markedly reduced in the CGM group over the study period. Mild hypoglycemia decreased from an average of 4.2 to 1.9 episodes per month, while severe hypoglycemia dropped from 1.2 to 0.3 episodes. In comparison, the SMBG group saw smaller reductions, from 4.0 to 3.6 for mild and 1.1 to 0.9 for severe episodes. Previous research has similarly found that CGM significantly reduces the risk of hypoglycemia by providing timely alerts and trend data that allow users to take preventive action [14]. Hyperglycemia episodes also decreased more substantially in the CGM group (from 5.5 to 2.6 events per month) compared to the SMBG group (from 5.3 to 4.7 events), further indicating better glycemic stability with CGM use. Quality of life, assessed using the Diabetes-Specific Quality of Life (DSQOL) questionnaire, showed notable improvements across all domains in the CGM group, including physical well-being, emotional health, social functioning, and treatment satisfaction Table 4. The total DSQOL score in the CGM group improved from 65.3 to 88.1, compared to 64.7 to 74.3 in the SMBG group (p<0.01). These findings are supported by previous research that highlights the psychological benefits of CGM, including reduced anxiety related to glucose fluctuations and greater confidence in self-management [15,16]. Adherence to diabetes self-management behaviors also improved in the CGM group Table 5. These patients conducted more frequent glucose checks (10.3 vs. 3.9 times per day) and missed fewer insulin doses (0.8 vs. 1.5 per week) compared to the SMBG group. CGM wear time was high, with participants wearing sensors on average 27 out of 30 days per month. Previous research has indicated that CGM use is associated with higher treatment adherence due to the convenience and feedback it provides, which supports the findings in this study [17,18].

Table 2: Changes in Glycemic Control Over Time

Table 3: Frequency of Hypoglycemia and Hyperglycemia Episodes

Table 4: Quality of Life Assessment (DSQOL Scores)

Table 5: Diabetes Self-Management and Device Adherence

At the 12-month follow-up Table 6, a higher proportion of CGM users achieved key clinical targets. Fifty-eight percent reached an HbA1c ≤7%, compared to 31% of those using SMBG (p<0.01), and 66% achieved a TIR ≥70%, compared to only 29% in the SMBG group. Furthermore, fewer CGM users experienced hospital admissions (2% vs. 11%), and a greater proportion reported at least a 20% improvement in quality of life (81% vs. 54%). These outcomes align with previous research that has shown CGM to be associated with sustained long-term clinical and psychosocial benefits [19]. Overall, the results of this study reinforce the growing body of evidence suggesting that CGM is a highly effective tool for improving both clinical outcomes and quality of life in individuals with T1DM. The consistent improvements observed in this study—across glycemic control, hypoglycemia prevention, quality of life, treatment satisfaction, and adherence—highlight the long-term value of CGM in diabetes management. Although the study was limited to a single-center design and included some self-reported data, the sample size, length of follow-up, and statistically significant findings contribute to its strength and relevance.

Table 6: Long-Term Outcomes at 12-Month Follow-Up

This study provides clear evidence that continuous glucose monitoring (CGM) offers significant long-term benefits for patients with Type 1 Diabetes Mellitus compared to traditional self-monitoring of blood glucose (SMBG). Over a 12-month period, CGM use was associated with greater reductions in HbA1c, a substantial increase in time spent within the target glucose range, and fewer episodes of both hypoglycemia and hyperglycemia. In addition to improving glycemic control, CGM significantly enhanced patient-reported outcomes, including quality of life, treatment satisfaction, and adherence to diabetes self-management behaviors. These findings support the integration of CGM into routine diabetes care as a superior approach to achieving optimal glycemic control while also addressing the emotional and practical challenges faced by individuals living with Type 1 Diabetes. Widespread adoption of CGM may lead to improved clinical outcomes, reduced healthcare utilization, and better overall patient well-being.

1. Senn, J.D. Forn et al. "Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control." Journal of Clinical Medicine, vol. 8, no. 3, 2019, p. 394.
2. Stahl-Pehe, A. Forn et al. "Impact of Quality of Life (QoL) on Glycemic Control (HbA1c) Among Adolescents and Emerging Adults with Long-Duration Type 1 Diabetes: A Prospective Cohort-Study." Pediatric Diabetes, vol. 18, no. 8, 2017, pp. 808–816.
3. Jensen, M.H. Forn et al. "Long-Term Glucose-Lowering Effect of Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes Patients in Poor Glycaemic Control from Region North Denmark: An Observational Real-World Cohort Study." PLOS ONE, vol. 17, no. 10, 2022, p. e0274626.
4. Parkin, C.G. Forn et al. "Continuous Glucose Monitoring Use in Type 1 Diabetes: Longitudinal Analysis Demonstrates Meaningful Improvements in HbA1c and Reductions in Health Care Utilization." Journal of Diabetes Science and Technology, vol. 11, no. 3, 2017, pp. 522–528.
5. De Ridder, et al. "Effect of Nationwide Reimbursement of Real-Time Continuous Glucose Monitoring on HbA1c, Hypoglycemia and Quality of Life in a Pediatric Type 1 Diabetes Population: The RESCUE-Pediatrics Study." Frontiers in Pediatrics, vol. 10, 2022, p. 991633.
6. Jacobson, A.M. Forn et al. "The Long-Term Effects of Type 1 Diabetes Treatment and Complications on Health-Related Quality of Life: A 23-Year Follow-Up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications Cohort." Diabetes Care, vol. 36, no. 10, 2013, pp. 3131–3138.
7. Laffel, L.M. Forn et al. "Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults with Type 1 Diabetes: A Randomized Clinical Trial." JAMA, vol. 323, no. 23, 2020, pp. 2388–2396.
8. Nansel, T.R., L.M. Lipsky, and A. Liu. "Greater Diet Quality Is Associated with More Optimal Glycemic Control in a Longitudinal Study of Youth with Type 1 Diabetes." The American Journal of Clinical Nutrition, vol. 104, no. 1, 2016, pp. 81–87.
9. van Dijk, P.R. Forn et al. "Fifteen-Year Follow-Up of Quality of Life in Type 1 Diabetes Mellitus." World Journal of Diabetes, vol. 5, no. 4, 2014, pp. 569–574.
10. Speight, J. Forn et al. "Impact of Glycaemic Technologies on Quality of Life and Related Outcomes in Adults with Type 1 Diabetes: A Narrative Review." Diabetic Medicine, vol. 40, no. 1, 2023, p. e14944.
11. Lukács, A., L.B. Szerencsi, and L. Barkai. "Continuous Glucose Monitoring (CGM) Satisfaction and Its Effect on Mental Health and Glycemic Control in Adults with Type 1 Diabetes." Physiology International, vol. 109, no. 4, 2022, pp. 501–510.
12. Abolfotouh, M.A. Forn et al. "Quality of Life and Glycemic Control in Adolescents with Type 1 Diabetes and the Impact of an Education Intervention." International Journal of General Medicine, 2011, pp. 141–152.
13. Nathanson, D. Forn et al. "Effect of Flash Glucose Monitoring in Adults with Type 1 Diabetes: A Nationwide, Longitudinal Observational Study of 14,372 Flash Users Compared with 7691 Glucose Sensor Naive Controls." Diabetologia, vol. 64, 2021, pp. 1595–1603.
14. Charleer, S. Forn et al. "Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal and Impaired Awareness of Hypoglycemia." Diabetes Technology & Therapeutics, vol. 25, no. 4, 2023, pp. 231–241.
15. Lind, M. Forn et al. "Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults with Type 1 Diabetes Treated with Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial." JAMA, vol. 317, no. 4, 2017, pp. 379–387.
16. Altamimi, A., et al. "Effectiveness of Continuous Glucose Monitoring in Glucose Control and Quality of Life Among Type 1 Diabetic Patients in Madina City: A Cross-Sectional Study." Cureus, vol. 16, no. 7, 2024.
17. Well-Controlled, M.I. "Efficacy of Intermittently Scanned Continuous Glucose Monitoring in Well-Controlled Children." The Impact of Continuous Glucose Monitoring for People with Type 1 Diabetes, vol. 21, no. 8, 2020, p. 101.
18. Goddijn, P.P. Forn et al. "Longitudinal Study on Glycaemic Control and Quality of Life in Patients with Type 2 Diabetes Mellitus Referred for Intensified Control." Diabetic Medicine, vol. 16, no. 1, 1999, pp. 23–30.
19. Carlsen, S. Forn et al. "Glycemic Control and Complications in Patients with Type 1 Diabetes – A Registry-Based Longitudinal Study of Adolescents and Young Adults." Pediatric Diabetes, vol. 18, no. 3, 2017, pp. 188–195.